News

Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response. The FDA’s Office of

The CHMP’s positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents

The patent covers a method of treating eye conditions using EyeGate’s proprietary Dexamethasone Phosphate pharmaceutical formulation delivered by ocular iontophoresis. The patent is not limited to any particular

Of the total amount, Allergan will pay $460m upon closing of the deal, while $100m will be paid by 2016. The deal will also include potential research and

As part of the deal, Knight will be responsible or handling all regulatory and commercial activities for AzaSite in Canada. AzaSite 1% is a prescription sterile eye drop

The drug is approved for adults with laBCC, which has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. The

If Brinavess successfully completes the Phase I trial, which will be conducted in healthy volunteers, Eddingpharm intends to start a pivotal Phase III study by year end. Cardiome

The drug is approved for adults who require additional lowering of low-density lipoprotein (LDL) cholesterol. Praluent is the FDA-approved treatment in a new class of drugs known as

Technivie is an all-oral, interferon-free, direct-acting antiviral treatment consisting of the fixed-dose combination of paritaprevir/ritonavir (150/100mg) co-formulated with ombitasvir (25mg) dosed once daily and taken with a meal,